Asthma Clinical Research Network (ACRN) Dose of Inhaled Corticosteroids with Equisystemic Effects (DICE)
Open BioLINCC Study See bottom of this webpage for request information
October 13, 2008
August 24, 2006
Clinical Trial URLs
Primary Publication URLs
Commercial Use Data Restrictions No
Data Restrictions Based On Area Of Research No
The goal of this study was to establish a reliable method to evaluate systemic bioavailability and to determine equisystemic effects (microgram dose producing equal systemic cortisol suppression) in inhaled corticosteriods (ICS).
Inhaled corticosteriods (ICS) are being recommended for treatment of all ages of persistent asthma. The choice of an ICS is often based on convenience or cost factors. However, the potential for adverse systemic effects is not commonly considered. Becuase of these effects, it is important to be able to compare the different available prepareations and delivery systems with respect to both of their systemic effects and their efficacy, in order to determine an optimal asthma treatment strategy.
156 corticosteriod-naive patients with asthmas were recruited as 6 ACRN centers. These patients were approximately distributed by sex (58% male) and by ethnicity (31% minorities).
The ICS and placebo groups were comaparable at baseline with respect to sex, ethnicity, age, and BMI. the most reliable methods of evaluation was the 12-hour plasma cortisol under the curve (AUC) for the hourly overnight plasma cortisol measurements from 8 P.M. to 8 A.M.
Requests for Open BioLINCC Studies are submitted through this website. Click the Request button to begin.
Resources AvailableStudy Datasets Only
Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.